lmmuCell Corporation company was founded in 1982 and is based in Portland, Maine. ImmuCell Corporation, an animal health biotechnology company, engages in the development, manufacture, and sale of products that improve animal health and productivity in the United States and internationally. It offers First Defense, an orally delivered scours preventive product that is manufactured from cows colostrums using proprietary vaccine and milk protein purification technologies. The company also provides products that aid in the management of inflammation of the mammary gland caused by bacterial infections, including Wipe Out Dairy Wipes, which consist of pre-moistened, biodegradable towelettes that are impregnated with Nisin to prepare the teat area of a cow in advance of milking; MASTiK, a mastitis antibiotic susceptibility test kit; and California Mastitis Test (CMT), which is performed at cow-side for early detection of mastitis. CMT can be used for bulk tank and individual cow sample monitoring, and for determining the quarter of the udder that is mastitic. In addition, it offers Rapid Johne's Test, which identifies cattle with symptomatic Johne's disease in a herd. Additionally, ImmuCell Corporation focuses on developing Mast Out, an intramammary infusion product containing Nisin for use in the treatment of mastitis in lactating dairy cows. It sells and markets its products primarily to veterinarians and producers in the dairy and beef industries.

Tropical Oasis hopes to be exactly that, offering much needed refreshment to bodies in need of liquid. Through its three brands, Tropical Oasis, Liquid Solutions, and Radical Performance Technology, the company offers a variety of nutritional and sports drinks which can boost energy, replenish certain nutrients and vitamins, and assist in weight loss efforts.

Ipsen develops pharmaceutical products that target oncology, endocrinology, and neuromuscular disorders. The group additionally markets products to treat gastroenterology, cardiovascular, and cognitive disorders. Ipsen operates research-and-development (R&D) centers in Paris, Boston, Barcelona, and London, which have churned out more than 20 products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly as well as through third parties, and has formed strategic development alliances with the likes of Medicis and Applied Biosystems (now part of Life Technologies Corporation).

Caprius, Inc. company owns a majority interest in MCM Environmental Technologies, which provides systems for disposal of medical waste. Its SteriMed system can crush, grind, shred, and mix all types of medical waste, including metal sharps and needles, plastic tubing and IV bags, and glass items. Once this process is complete, MCM's Steri-Cid chemical process disinfects the waste, which can then be discarded as regular waste at as little as 10% of the original volume. MCM manufactures the SteriMed system in Israel; the company distributes parts and supplies from facilities in Israel. Officers and directors, led by Austin W. Marxe and David M. Greenhouse hold about 22% of Caprius.

Alacer Corp. will "C" you through your cold. Maker of the popular Emergen-C fizzy drink mix, the company set the cornerstone on branded vitamin C products. In addition to Emergen-C, which blends mineral ascorbates with B vitamins and mineral complexes, the company's other products include ElectroMIX (electrolyte drink mix) and its Super Gram time-released tablets. Alacer also develops other vitamin and herbal supplements, all with a walloping dose of vitamin C stirred in. Its products are sold through natural foods retailers, mass market retailers, and chain drug stores.

Pfizer Limited company is the top provider of medicines to the UK's National Health Service, offering many of its parent company's products to treat conditions including cardiovascular ailments and cancers. It also provides animal health products. Pfizer Limited conducts research and development activities, focusing on medications in the areas of allergy, respiratory, urinary, metabolic, and gastrointestinal ailments, as well as vaccines, anti-retrovirals, and pain treatments.

Dyadic International, Inc. (Dyadic) is an early-stage biotechnology company. The Company has operations in the United States, the Netherlands and Poland. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies and the sale of its enzymes. The Company is a holding company that holds all of Dyadic International (USA), Inc. (Dyadic-Florida). Dyadic-Florida owns all of Geneva Investment Holdings Limited, Dyadic Nederland BV, and Dyadic International Sp. z o.o. Dyadic’s R&D activities focus on its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes.

Theravance was founded in 1996 and is headquartered in South San Francisco, California. Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines across various therapeutic areas, including respiratory disease, bacterial infections, and gastrointestinal motility dysfunction. It offers Telavancin (cSSSI), a bactericidal injectable antibiotic for the treatment of complicated skin and skin structure infections; Telavancin (HAP) that is used to treat hospital-acquired pneumonia or nosocomial pneumonia; and Horizon to develop and commercialize long-acting beta2 agonist (LABA) product candidate as a single agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long acting muscarinic antagonist (LAMA) for COPD. In addition, it offers GSK961081, a bifunctional muscarinic antagonist-beta2 agonist compound, which is in phase 2 clinical studies; and TD-5108, a gastrointestinal motility dysfunction program for the treatment of chronic constipation and other disorders related to reduced gastrointestinal motility. The company has collaboration arrangements with Astellas Pharma, Inc. for the development and commercialization of Telavancin; GlaxoSmithKline plc to develop and commercialize LABA product candidates; and AstraZeneca AB to develop and commercialize intravenous anesthetic compounds. The company also has a strategic alliance with GlaxoSmithKline plc. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002.

Xanodyne Pharmaceuticals, Inc. company develops and manufactures drugs for pain management and women's health. Its commercial offerings include pain treatments Darvocet, Roxicodone, and Oramorph SR, as well as Duet prenatal vitamins. Zipsor, a treatment for mild to moderate inflammatory pain such as arthritic pain, and Lysteda, a treatment for menorrhagia (excessive menstrual bleeding), were both approved by the FDA in 2009. Xanodyne has several other drugs in development, including one for mild to moderate pain in late-stage clinical trials. The company funds its development efforts through sales of its commercial products, which are marketed through an internal sales force.

Viventia Biotechnologies Inc., a biopharmaceutical company, offers a portfolio of novel antibody-based drugs for the treatment of cancer. Its lead product, Proxinium is used for the treatment of head and neck cancer. The company also offers Vicinium, a product for the treatment of bladder cancer; and VB6-845, a product for the treatment of solid tumors. Viventia specializes in the discovery and development of a portfolio of monoclonal antibodies for the treatment of common cancers. It also has a location in Winnipeg, Canada. The company was formerly known as Novopharm Biotech, Inc. and changed its name to Viventia Biotech, Inc. in 2000. The company was is headquartered in Mississauga, Canada. As of December 28, 2005, Viventia Biotechnologies Inc. operates as a subsidiary of Dan Family Holdings, Ltd.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.